Ascendis Pharma A/S
ASNDHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframePart of the healthcare sector, Ascendis Pharma A/S (ASND) is listed under Biotechnology. The company carries a $17.75B market cap, placing it firmly in the large-cap category. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Market Cap
$17.75B
Beta
—
P/E (TTM)
20.88
P/E (Fwd)
29.02
EPS (TTM)
$12.96
EPS (Fwd)
$9.32
ROE
118.8%
ROA
9.6%
Cash
$812.3M
Total Debt
$450.1M
Free CF
$12.8M
52W Change
31.8%
Annual Financials
Cash vs Debt
Where ASND stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ASND finished 12.04% above its 150-day moving average ($238.59) and 15.28% above its 200-day moving average ($231.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ASND overbought or oversold?
At the September 3, 2026 close, ASND's RSI(14) was 69.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $812.3M in cash comfortably exceeding the $450.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $12.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 118.8%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $51.2M (2022) to $720.1M (2025), reflecting a 1307% increase over the period.
As with any equity investment, ASND carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ascendis Pharma A/S's trajectory.